# Meili Nanotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/meili-nanotechnology

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.meilitech.cn
- Latest round: Series A (Jul 17, 2018)
- Investors on record: 1

## About

Established in 2017 and based in Shenzhen, China, Meili Nanotechnology operates as a nanopore early cancer detection devices developer that provides commercial gene sequencing instruments and supporting reagents. The core research team comes from Ohio State University, University of Washington, University of Jena, Germany and University of Chinese Academy of Sciences. The company cooperates with institute of physics of Chinese Academy of Sciences, Shenzhen University of Technology and Xiangya Hospital of Central South University, etc.  In March 2021, the company cooperates with Changde high-tech zone. In November 2022, it was rewarded as the top 10 most growing biotech companies. In February 2023, the company raised closed series A+ round of funding led by Antubio.

The company combines nanopore gene sequencing technology with pathogen detection. Products cover many testing fields, including immunological, microbiological, biochemical, molecular and coagulation, etc. Its products include MePore single-channel sequencing systems for research users, MeMob gene sequencers, MeZero pA class current amplifier and multichannel microfluidic chips.

## Funding rounds

- Series A, Jul 17, 2018 — Holch Capital

## Investors

- Holch Capital (https://capitalatlas.ai/funds/holch-capital) — Series A